Guardant Health Q3 2025 Financial Results

Guardant Health, Inc. reported its financial results for the third quarter of 2025, showing a 39% increase in total revenue to $265.2 million compared to the same period in 2024. The growth was driven by strong performance across Oncology, Screening, and Biopharma & Data segments. Oncology revenue grew 31% to $184.4 million, while Screening revenue reached $24.1 million, primarily from Shield tests. Biopharma & Data revenue increased 18% to $54.7 million. The company raised its 2025 revenue guidance to $965-$970 million, representing a 31% year-over-year growth. Non-GAAP gross margin improved to 66%, and the company reported a non-GAAP net loss of $48.3 million, compared to a $55.0 million loss in the prior year period. Guardant Health also highlighted recent operational achievements, including the expansion of Shield for multi-cancer detection and strategic collaborations with Quest Diagnostics and PathGroup.